CMRX Stock Overview
A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Chimerix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.37 |
| 52 Week High | US$3.80 |
| 52 Week Low | US$0.75 |
| Beta | 0.36 |
| 1 Month Change | 15.81% |
| 3 Month Change | 286.34% |
| 1 Year Change | 258.47% |
| 3 Year Change | -40.67% |
| 5 Year Change | 67.66% |
| Change since IPO | -82.06% |
Recent News & Updates
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Dec 11We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate
Jul 16
Recent updates
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Dec 11We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate
Jul 16Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation
Aug 23Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Jul 20Chimerix: Down But Not Out
Jun 06Chimerix: Searching For Clarity
Jan 05Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Dec 24Is Chimerix (NASDAQ:CMRX) A Risky Investment?
Sep 16Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Jun 08Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox
Jun 04Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?
May 13Chimerix Investor Presentation - Slideshow
May 08Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%
Jan 08Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?
Jan 01
Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure
Dec 07Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans
Dec 05Shareholder Returns
| CMRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.4% | -2.0% | -2.5% |
| 1Y | 258.5% | -8.7% | 21.6% |
Return vs Industry: CMRX exceeded the US Biotechs industry which returned -8.7% over the past year.
Return vs Market: CMRX exceeded the US Market which returned 21.6% over the past year.
Price Volatility
| CMRX volatility | |
|---|---|
| CMRX Average Weekly Movement | 63.2% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 19.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CMRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CMRX's weekly volatility has increased from 32% to 63% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 72 | Mike Andriole | www.chimerix.com |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Chimerix, Inc. Fundamentals Summary
| CMRX fundamental statistics | |
|---|---|
| Market cap | US$303.08m |
| Earnings (TTM) | -US$83.59m |
| Revenue (TTM) | US$159.00k |
1,906x
P/S Ratio-3.6x
P/E RatioIs CMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMRX income statement (TTM) | |
|---|---|
| Revenue | US$159.00k |
| Cost of Revenue | US$73.55m |
| Gross Profit | -US$73.39m |
| Other Expenses | US$10.21m |
| Earnings | -US$83.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | -46,154.72% |
| Net Profit Margin | -52,574.84% |
| Debt/Equity Ratio | 0% |
How did CMRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/15 03:01 |
| End of Day Share Price | 2025/01/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chimerix, Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | Barclays |
| Jonathan Aschoff | Brean Capital |
| Ritu Baral | Canaccord Genuity |